IBDEI20D ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32052,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32052,1,3,0)
 ;;=3^Chlamydia (Culture +)
 ;;^UTILITY(U,$J,358.3,32052,1,4,0)
 ;;=4^A74.89
 ;;^UTILITY(U,$J,358.3,32052,2)
 ;;=^5000387
 ;;^UTILITY(U,$J,358.3,32053,0)
 ;;=Z11.8^^126^1644^16
 ;;^UTILITY(U,$J,358.3,32053,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32053,1,3,0)
 ;;=3^Screen,Chlamydia
 ;;^UTILITY(U,$J,358.3,32053,1,4,0)
 ;;=4^Z11.8
 ;;^UTILITY(U,$J,358.3,32053,2)
 ;;=^5062677
 ;;^UTILITY(U,$J,358.3,32054,0)
 ;;=A56.02^^126^1644^4
 ;;^UTILITY(U,$J,358.3,32054,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32054,1,3,0)
 ;;=3^Chlamydial Vulvovaginitis
 ;;^UTILITY(U,$J,358.3,32054,1,4,0)
 ;;=4^A56.02
 ;;^UTILITY(U,$J,358.3,32054,2)
 ;;=^5000340
 ;;^UTILITY(U,$J,358.3,32055,0)
 ;;=Z20.2^^126^1644^5
 ;;^UTILITY(U,$J,358.3,32055,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32055,1,3,0)
 ;;=3^Contact with/Exposure to Infection,Sexual Mode of Transmission
 ;;^UTILITY(U,$J,358.3,32055,1,4,0)
 ;;=4^Z20.2
 ;;^UTILITY(U,$J,358.3,32055,2)
 ;;=^5062764
 ;;^UTILITY(U,$J,358.3,32056,0)
 ;;=N71.9^^126^1644^6
 ;;^UTILITY(U,$J,358.3,32056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32056,1,3,0)
 ;;=3^Endometritis
 ;;^UTILITY(U,$J,358.3,32056,1,4,0)
 ;;=4^N71.9
 ;;^UTILITY(U,$J,358.3,32056,2)
 ;;=^5015811
 ;;^UTILITY(U,$J,358.3,32057,0)
 ;;=A54.00^^126^1644^9
 ;;^UTILITY(U,$J,358.3,32057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32057,1,3,0)
 ;;=3^Gonorrhea (Culture +),Lower GU Tract
 ;;^UTILITY(U,$J,358.3,32057,1,4,0)
 ;;=4^A54.00
 ;;^UTILITY(U,$J,358.3,32057,2)
 ;;=^5000311
 ;;^UTILITY(U,$J,358.3,32058,0)
 ;;=Z11.3^^126^1644^17
 ;;^UTILITY(U,$J,358.3,32058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32058,1,3,0)
 ;;=3^Screen,Gonorrhea
 ;;^UTILITY(U,$J,358.3,32058,1,4,0)
 ;;=4^Z11.3
 ;;^UTILITY(U,$J,358.3,32058,2)
 ;;=^5062672
 ;;^UTILITY(U,$J,358.3,32059,0)
 ;;=A60.04^^126^1644^10
 ;;^UTILITY(U,$J,358.3,32059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32059,1,3,0)
 ;;=3^Herpesviral Vulvovaginitis
 ;;^UTILITY(U,$J,358.3,32059,1,4,0)
 ;;=4^A60.04
 ;;^UTILITY(U,$J,358.3,32059,2)
 ;;=^5000356
 ;;^UTILITY(U,$J,358.3,32060,0)
 ;;=N89.8^^126^1644^11
 ;;^UTILITY(U,$J,358.3,32060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32060,1,3,0)
 ;;=3^Leukorrhea
 ;;^UTILITY(U,$J,358.3,32060,1,4,0)
 ;;=4^N89.8
 ;;^UTILITY(U,$J,358.3,32060,2)
 ;;=^88111
 ;;^UTILITY(U,$J,358.3,32061,0)
 ;;=N73.0^^126^1644^12
 ;;^UTILITY(U,$J,358.3,32061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32061,1,3,0)
 ;;=3^Pelvic Cellulitis
 ;;^UTILITY(U,$J,358.3,32061,1,4,0)
 ;;=4^N73.0
 ;;^UTILITY(U,$J,358.3,32061,2)
 ;;=^270467
 ;;^UTILITY(U,$J,358.3,32062,0)
 ;;=N76.1^^126^1644^20
 ;;^UTILITY(U,$J,358.3,32062,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32062,1,3,0)
 ;;=3^Vaginitis,Subacute and Chronic
 ;;^UTILITY(U,$J,358.3,32062,1,4,0)
 ;;=4^N76.1
 ;;^UTILITY(U,$J,358.3,32062,2)
 ;;=^5015827
 ;;^UTILITY(U,$J,358.3,32063,0)
 ;;=A53.9^^126^1644^18
 ;;^UTILITY(U,$J,358.3,32063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32063,1,3,0)
 ;;=3^Syphilis
 ;;^UTILITY(U,$J,358.3,32063,1,4,0)
 ;;=4^A53.9
 ;;^UTILITY(U,$J,358.3,32063,2)
 ;;=^5000310
 ;;^UTILITY(U,$J,358.3,32064,0)
 ;;=A59.01^^126^1644^19
 ;;^UTILITY(U,$J,358.3,32064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32064,1,3,0)
 ;;=3^Trichomonal Vulvovaginitis
 ;;^UTILITY(U,$J,358.3,32064,1,4,0)
 ;;=4^A59.01
